Urocortin-2, Human, mAb 2D7
Monoclonal antibody 2D7 recognizes the pro-region of Urocortin-2. Urocortins 1, 2 and 3 (Ucn I, Ucn II, and Ucn III), members of the corticotropin releasing factor (CRF)4 family, have diverse bioactivities and participate in the neuroendocrine responses to stress, appetite suppression, immunomodulation, energy and water homeostasis, and cardiovascular function. Their actions are mediated through the 7-transmembrane G-protein coupled receptors CRFR1 and CRFR2. Ucn1 binds to both receptors, whereas Ucn II and Ucn III are specific to CRFR2, widely expressed in the brain, heart, vasculature, and peripheral tissues. Binding of Ucn II to its receptor triggers an intricate signaling cascade via protein kinase C, phosphatidylinositol-3-kinase/Akt and mitogen-activated protein kinase pathways to modulate cytokine expression, cell proliferation, and apoptotic responses. The presence of Ucn II and CRFR2 in the heart and vasculature suggest a potentially important role for Ucn II in the physiology and pathophysiology of the circulation in health and cardiovascular disease. Urocortins exert beneficial effects in experimental cardiovascular disease models and may have therapeutic potential. The sequence of the mature human Ucn II neuropeptide is IVLSLDVPIGLLQILLEQARARAAREQATTNARILARV.
W: Protein samples were separated by 16% SDS-PAGE for an hour at 200 V and electroblotted onto Immun-Blot® PVDF membrane at 100 mA for 1 h. Western blotting was performed using mouse 2D7 (1/1000 dilution) as primary antibody and goat anti mouse IgG conjugated to horse radish peroxidase (1/2000). The band sizes are 35 and 80 kDa. (Ref.1)
Related products
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA